In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...

CWA Asset Management Group LLC acquired a new position in Organon & Co. (NYSE:OGN – Free Report) in the third quarter, ...

Incaier, the healthcare arm of Haier Group, has participated in the expo for five consecutive years. This year, more than 50 ...

The United Nations Population Fund (UNFPA) Mexico and EDP Renewables North America LLC have joined forces in a groundbreaking collaborat ...

Havas Health named Anna Maria Marra as CEO of Europe on Tuesday morning, a role in which she will lead and oversee all ...

Havas Health has appointed Anna Maria Marra as CEO of Europe to lead and oversee all aspects of the region's business ...

Pfizer hired Marra all the way back in 2002, at which time the new Havas Health exec had spent a few years working at Merck ...

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

JP Morgan has recently reduced Organon & Co (OGN) stock to Underweight rating, as announced on September 6, 2024, according to Finviz. Earlier, on November 3, 2023, Goldman had reduced the stock from ...

MAPS 2025 Americas Annual Meeting Annual meeting sessions aligned with MAPS Medical Affairs Competencies Framework provide training oppo ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...

As of the latest trading close, OGN, a Healthcare sector stock, is trading -30.22% below its 52-week high but remains 48.78% above its 52-week low. The Average True Range (ATR) (14 days) of 0.61 ...